Literature DB >> 23429038

Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification.

Qi-wei Wang1, Ke Yao, Wen Xu, Pei-qing Chen, Xing-chao Shentu, Xin Xie, Yan Weng, Li Zhang, Chong-fei Jin, Wei Wu, Ya-nan Zhu, Yin-hui Yu.   

Abstract

PURPOSE: To compare bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for the control of postoperative inflammation and prevention of cystoid macular edema (CME) after phacoemulsification.
METHODS: Patients were randomized to receive bromfenac sodium 0.1% for 1 month (OBS1) or 2 months (OBS2), or fluorometholone 0.1% for 1 month (OFM) or dexamethasone 0.1% for 1 month (ODM). Best-corrected visual acuity, intraocular pressure, endothelial cell density, photon count value and retinal foveal thickness were measured.
RESULTS: Mean photon count values were lower in the OBS1 and OBS2 groups compared with the ODM group during the first week. Bromfenac sodium cleared the ocular inflammation more rapidly than fluorometholone and dexamethasone. The foveal thickness was thinner in the second month and the incidence of CME was lower in the OBS1 and OBS2 groups compared with the OFM and ODM groups.
CONCLUSION: Bromfenac sodium was more effective and safer than fluorometholone and dexamethasone as an anti-inflammatory, decreasing macular thickness and preventing CME in age-related cataract patients after cataract surgery.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429038     DOI: 10.1159/000346847

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  16 in total

Review 1.  Laser flare and cell photometry to measure inflammation after cataract surgery: a tool to predict the risk of cystoid macular edema.

Authors:  Michele De Maria; Marco Coassin; Danilo Iannetta; Luigi Fontana
Journal:  Int Ophthalmol       Date:  2021-03-21       Impact factor: 2.031

2.  Effect of nepafenac on the foveal profile of glaucomatous patients undergoing phacoemulsification.

Authors:  Elena Milla; Oana Stirbu; Isabel Jimenez Franco; Santiago J García Hernández; Jose Rios; Susana Duch
Journal:  Int Ophthalmol       Date:  2016-10-22       Impact factor: 2.031

3.  Comparison of the anti-inflammatory effects of fluorometholone 0.1% combined with levofloxacin 0.5% and tobramycin/dexamethasone eye drops after cataract surgery.

Authors:  Pei-Qing Chen; Xue-Mei Han; Ya-Nan Zhu; Jia Xu
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

4.  Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs and corticosteroid drugs for prevention of cystoid macular edema after cataract surgery.

Authors:  Shan-Shan Li; Hui-Hui Wang; Yan-Ling Wang; Da-Wei Zhang; Xi Chen
Journal:  Int Ophthalmol       Date:  2022-09-06       Impact factor: 2.029

Review 5.  Cataract surgery and nonsteroidal antiinflammatory drugs.

Authors:  Richard S Hoffman; Rosa Braga-Mele; Kendall Donaldson; Geoffrey Emerick; Bonnie Henderson; Malik Kahook; Nick Mamalis; Kevin M Miller; Tony Realini; Neal H Shorstein; Richard K Stiverson; Barbara Wirostko
Journal:  J Cataract Refract Surg       Date:  2016-09       Impact factor: 3.351

6.  Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification.

Authors:  Ana María Chinchurreta Capote; Mercedes Lorenzo Soto; Francisco Rivas Ruiz; Enrique Caso Peláez; Alicia García Vazquez; Antonio Ramos Suárez
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

Review 7.  Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.

Authors:  Viral V Juthani; Elizabeth Clearfield; Roy S Chuck
Journal:  Cochrane Database Syst Rev       Date:  2017-07-03

Review 8.  Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence.

Authors:  Rajesh K Rajpal; Bryan Ross; Sachin D Rajpal; Khoa Hoang
Journal:  Patient Prefer Adherence       Date:  2014-06-25       Impact factor: 2.711

9.  The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model.

Authors:  George A Baklayan; Mauricio Muñoz
Journal:  Clin Ophthalmol       Date:  2014-09-04

Review 10.  Pseudophakic cystoid macular edema: update 2016.

Authors:  Andrzej Grzybowski; Bartosz L Sikorski; Francisco J Ascaso; Valentín Huerva
Journal:  Clin Interv Aging       Date:  2016-09-09       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.